iBio (IBIO) Stock Continues Flying Higher… And For Good Reason!

iBio IBIO Stock News

Yesterday was a big day for Ibio Inc (NYSEAMERICAN: IBIO) stock. Trading on tremendous volume, the stock closed on gains of more than 20%, and today is already starting to look positive. In the premarket, we’re seeing gains of more than 5%. So, what’s next? Will we see more gains out of IBIO? I’m no fortune teller, but I do see more strong movement in the near, and long term for this stock. Here’s why:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Looking At Why IBIO Stock Climbed Yesterday

As mentioned above, yesterday was a big day for iBio. The stock flew after the company discussed progress that it is making in the fight against COVID-19. In particular, the progress has to do with manufacturing.

While the release seemed to be more about its partnership with NIIMBL, there was a big statement made in the press release that had little to do with this partnership. Tom Isett, CEO at IBIO, said:

If our own proprietary SARS-CoV-2 Virus-Like Particle (“VLP”) program, IBIO-200, results in an approved vaccine, we estimate that we could make about 500 million doses of high-quality product annually at our Texas facility…”

That’s a huge statement. Think about it, with the COVID-19 pandemic, a vaccine couldn’t come fast enough. Even with several companies working to develop vaccines, we have to think about manufacturing.

IBIO is one step ahead here. Not only have they thought about manufacturing while developing their vaccine candidate, they are already prepared to mass produce this vaccine and get it out to patients as soon as possible.

Of course, if you’ve followed my articles, you know that this falls right in line with what I’ve been saying all along:

The FastPharming Facility Is A Massive Advantage

When we talk about biotech companies that are working to develop a vaccine, we’re talking about just that. For most of these companies, the center of attention is drug development and regulatory work. Most outsource manufacturing, which can create a real headache when it comes to a quick product launch.

iBio simply doesn’t have this problem. Several years ago, the company broke ground on the FastPharming Facility. The facility was designed to be able to produce mass amounts of plant-based vaccines and other biological agents that could help should a pandemic occur. Well, that pandemic is occuring my friends.

Due to this facility, there will be no middle man needed to go from regulatory approval and commercial availability. Not to mention the company could make this happen very quickly.

So, What About The Vaccine Candidate

While we haven’t heard much lately, we do know a few things. IBIO is working with a Chinese company known as CC Pharming to develop the vaccine. This partnership is a huge step in the right direction for two reasons:

  • First and foremost, CC Pharming is no stranger to the development of vaccines. In fact, the company has done extensive work in the coronavirus space, developing vaccines for cousin strains of the virus that is at the center of today’s pandemic.
  • It’s also important to remember where the virus originated, China. CC Pharming gives IBIO access to the vast Chinese market once the vaccine is developed. While China seems to be beating the coronavirus, a vaccine will be in high demand around the world, including in China.

Beyond this partnership, we know that the vaccine the two companies are developing is making some progress. In fact, in the most recent news, IBIO told us that the candidate was headed into immunization studies at Texas A&M University.

Is A Catalyst Around The Corner?


The truth of the matter is that the most recent update came late last month, and while it takes time to develop any vaccine or therapeutic option, investors are itching for an update. Considering the press release that pumped up investors yesterday, it only makes sense that iBio will have more updates up its sleeve relatvely soon.

Should one of these updates be data from what’s going on at Texas A&M, and should that data be positive, the stock could soar. Nonetheless, any announcement having to do with work to develop or set up commercial-scale manufacturing for its COVID-19 will likely send the stock up, making IBIO one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.